Q1 2024 Ultragenyx Pharmaceutical Inc Earnings Call Transcript
Key Points
- Ultragenyx Pharmaceutical Inc (RARE) reported strong positive interim data from the Phase 1/2 study of GTX-102 in Angelman Syndrome, showing significant improvement in patient development.
- The company completed enrollment for the Phase 2/3 Orbit study and Phase 3 Cosmic study in Osteogenesis Imperfecta, indicating accelerated interest and support from the study investigators.
- Ultragenyx Pharmaceutical Inc (RARE) demonstrated a robust safety profile for GTX-102, with manageable lower extremity weakness observed in only a small fraction of patients.
- Crysvita's performance in North America remains strong with a significant increase in new prescribers and patient start forms, indicating growing market penetration and demand.
- Ultragenyx Pharmaceutical Inc (RARE) reaffirmed its 2024 revenue guidance, expecting significant growth and projecting total revenue to be between $500 million and $530 million.
- The company reported a net loss of $171 million for the first quarter of 2024, highlighting ongoing financial challenges.
- Operating expenses for Ultragenyx Pharmaceutical Inc (RARE) were high, totaling $274 million for the quarter, which included substantial R&D and SG&A expenses.
- The company experienced a larger use of cash in operations during the first quarter, amounting to $191 million, primarily due to annual bonuses and a high accounts receivable balance.
- Ultragenyx Pharmaceutical Inc (RARE) faces uncertainties regarding the finalization of the Phase 3 trial design and endpoint selection for GTX-102, which could impact regulatory approval timelines.
- Despite strong growth projections, Ultragenyx Pharmaceutical Inc (RARE) continues to navigate the complexities of transitioning manufacturing processes in-house, which could affect the timing of future product filings and launches.
Good afternoon, and welcome to the Ultragenyx First Quarter 2024 Financial Results Conference Call. (Operator Instructions) It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President, Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
